Home > Companies > Irvine Scientific

Irvine Scientific

Irvine Scientific, a member of JX Holdings Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

24-26 October 2022: BIO-Europe

Conference

Percutaneous interventions for stroke prevention and congenital heart disease

Webinar

Family Medicine and Internal Medicine: An Evidence-Based Approach

Conference

ACB-ISBE 2022: Biotech for Stronger Recovery

Conference

Emerging role of biomarkers for cardiovascular risk assessment in T2DM and optimisation of cardioprotective treatment: current evidence and future trends

Webinar

5th Annual Congress on Wellness and Alternative Healthcare Informatics

Conference

Related News

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology | May 27, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

INDUSTRY OUTLOOK

CUROCELL, BREAKS GROUND ON 'CAR-T MANUFACTURING GMP FACILITY'

Curocell, Inc. | December 24, 2021

Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt. The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-meter site of CAR-T Center. By the first half of 2023, construction is expected to be completed and...

BOLD-100 OUTPERFORMS REMDESIVIR HEAD-TO-HEAD IN SARS-COV-2 (COVID-19), THE ONLY HIGHLY POTENT ANTIVIRAL AGENT

PR Newswire | August 18, 2020

Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral. In a series of experiments conducted by Dr. Stephen Barr, Associate Professor in the Department of Microbiology and Immunology at Western University, both BOLD-100 and remdesivir were tested head-to-head in a cytopathic effect assay against a live Wuhan strain of SARS-CoV-2 (COVID-19) in Vero E6 cells. Consistent with prior expe...

CELL AND GENE THERAPY

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...